As per our new research report “Israel Life Sciences Market Analysis”, Israeli Life Science companies in general have witnessed impressive returns via IPOs, mergers, and acquisitions. It has been found in our research that, the value of M&A’s and IPO’s in Israeli Life Sciences companies totaled US$ 822 Million in 2009. The main drivers for these collaborations in the life sciences industry of the nation are myriad of revolutionary and valuable innovations in the field of Life Sciences, extensive skilled workforce, and prospering high technology environment.
2010 witnessed some very important mergers and acquisitions in the field of life sciences. For instance, Roche acquired Medingo for US$ 160 Million for strengthening Roche Diabetes Care’s position in the fast growing segment of insulin delivery systems. Further, Abbott Laboratories also agreed to acquire Israel-based Starlims Technologies Ltd for US$ 123 Million to boost its position in the global diagnostics market during the same year.
Besides, our report provides a thorough research and prudent analysis of the Israeli Life Sciences industry. Our study indicates that, a rich pipeline of seed companies is fueling the incessant growth of the Israeli Life Sciences industry for the past few years.
Further, the systematic and thorough research studies the Israeli Life Sciences industry to present an insight into various segments of the Israeli Life Sciences Industry. Our research indicates that, around 57% of the Israeli life sciences companies worked in the medical devices sector in 2010. A series of medical device advancements has occurred in this sector that includes the innovation around the CT scanner (Elscint) and imaging systems (such as Given Imaging).
Our report “Israel Life Sciences Market Analysis”, highlights the Israeli Life Sciences industry by segmenting it into medical devices, biotechnology, pharma, medical IT & Agro Biotech. Each of these segments have been thoroughly studied and analyzed in the report. Moreover, the report provides an overview of the investment scenario and recent M&As activity, which will help clients to identify the future demand scenario.
The report studies the current market drivers and its effects on the incessant growth of the industry. The research contains exhaustive information about the market players, government initiatives, and macro-economic indicators that will help clients to draw up market strategies and assess opportunity areas in the US diabetes market. The report also includes a section of exports and analysis by therapeutics that presents a rough idea about the prospective business trends to facilitate clients comprehends how the market will progress in coming years.
For more information visit: http://www.rncos.com/Report/IM340.htm |
